CAJ | 학술논문

钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是目前Ⅱ型糖尿病药物研究的热点之一。通过抑制这种在肾脏特异性表达的钠-葡萄糖协同转运蛋白2（SGLT2），可以减少肾脏对葡萄糖的重吸收，增加葡萄糖在尿中的排泄，从而降低血糖。本文将针对已上市的C-芳基糖苷类SGLT2抑制剂伊格列净和恩格列净的合成路线进行简要评述。
납-포도당협동전운단백2（SGLT2）억제제시목전Ⅱ형당뇨병약물연구적열점지일。통과억제저충재신장특이성표체적납-포도당협동전운단백2（SGLT2），가이감소신장대포도당적중흡수，증가포도당재뇨중적배설，종이강저혈당。본문장침대이상시적C-방기당감류SGLT2억제제이격렬정화은격렬정적합성로선진행간요평술。
Sodium glucose Co-transporter 2 (SGLT2) has been a hot spot of research on the treatment for type II diabetes. Inhibiting SGLT2, which works in the kidney specially, can reduce renal glucose reab-sorption, excrete excess glucose through the urine and lower the plasma glucose. This paper briefly reviews the synthetic routes to the C-aryl glucosides sodium glucose Co-transporter 2 inhibitors on the market, such as Ipragliflozin, Empagliflozin.